Women’s Health Market Size, Share & Trends Analysis Report By Application (Postmenopausal Osteoporosis, Hormonal Infertility, Endometriosis & Uterine Fibroids, Contraceptives), By Age, By Region, And Segment Forecasts, 2023 - 2030

Report Overview 

The global women’s health market size was valued at USD 41.35 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 5.4% from 2023 to 2030. Market growth can be attributed to the increase in the geriatric population of women and introduction of new products for women’s health, such as Relugoliz and Orilissa amongst others. Furthermore, favourable policies initiated by governments to improve women’s health and raise awareness are likely to drive market growth during the forecast period.The market exhibited lower than the expected growth during the pandemic. Access to contraception and gynecological testing has declined, raising the rate of unsafe abortions and unwanted pregnancies, especially in developing countries. For instance, according to BMC, in the low- and middle-income countries, there has been around a 10% decline in the use of long- and short-acting reversible contraceptives, about 10% decline in essential services related to pregnancy care. All these factors led to a decline in market growth amid the pandemic. Women are more susceptible to various diseases such as osteoporosis, osteoarthritis, endometriosis, and menstrual health disorders.

Around 73% of postmenopausal women experience hot flashes, fatigue, and sleep disturbances, which increase dependence on medications, impairing the quality of life. With aging and the increasing prevalence of obesity, osteoporosis is anticipated to grow. Some of the major factors leading to hormonal imbalance in women are stress, change in dietary habits, and alcohol consumption, is likely to cause fertility issues in women. Polycystic Ovarian Syndrome (PCOS), ovulation problems, and endometriosis are some of the major causes of infertility. According to WHO, in 2021, globally, around 190 million women of reproductive age were affected by endometriosis.

These factors are anticipated to fuel market growth. According to the United Nations, Department of Social and Economic Affairs, approximately 1.1 billion women needed family planning in 2019, out of which 190 million had unmet contraception needs and about 842 million used modern methods of contraception. Owing to the high unmet need for publicly funded contraceptive services and products, federal & state governments are actively working toward improving family planning services and improving access to modern contraceptives.

For instance, in 2020, Germany’s total multilateral funding for sexual & reproductive and family planning was around USD 121.85 million, an increase of about 65% from 2019. Furthermore, agencies such as USAID run reproductive health & family planning programs in more than 30 countries, including South Africa & other African countries, where there is a high unmet need for contraception. However, there are various complications and adverse effects of prolonged use of contraceptives, which lead to an increase in the adoption of traditional contraceptive methods.

Long-term severe adverse effects of oral contraceptive pills, such as stroke, blood clots, decreased libido, vaginal discharge, and increased risk of breast cancer, may limit usage and lead to banning by regulatory agencies. Such factors could hamper market growth during the forecast period. A few key products in the market are Xgeva, Evista, Prolia, Zometa, Mirena, Reclast/Aclasta, NuvaRing, Minastrin 24 Fe, Forteo, Actonel, Premarin, and Ortho Tri-Cy Lo (28). The market for NuvaRing declined by 3% in 2019 and 73% in 2020 primarily due to the introduction of generics following patient expiry in 2018 in the U.S.

Application Insights

The contraceptives segment held the highest market share of more than 35.49% of the global revenue in 2022 due to increased awareness about family planning and rapid technological advancements in contraception. In addition, favorable government regulations in countries such as the U.S., coupled with growing awareness about various contraceptive methods, are projected to accelerate contraceptives demand. For instance, the U.S. Federal law mandates that all female-controlled contraceptive methods are covered under insurance without any out-of-pocket costs for patients.

Pills are the most common method of contraception used in developed regions such as the U.S. and Europe, whereas in developing countries intrauterine devices and implants are most commonly used. Endometriosis & uterine fibroids segment is likely to grow at a CAGR of 12.9% during the forecast period. The growth can be attributed to the launch of new products for these conditions. For instance, the approval of Orilissa in 2018 in the U.S., and the approval of Myfembree in the U.S. in May 2021 for the treatment of moderate to severe pain associated with uterine fibroids and heavy menstrual bleeding associated with uterine fibroids respectively is expected to drive market growth.

Age segment Insights

On the basis of age group, the global market has been further bifurcated into 50 years & above and others. The 50 years & above age segment is expected to register the fastest growth rate of 6.7% over the forecast period as an increase in life expectancy is boosting the overall menopausal population across the globe. In addition, with a rise in the geriatric population, diseases, such as postmenopausal osteoporosis are also increasing. All these factors are expected to drive the growth of this segment in the years to come.

The others segment, on the other hand, accounted for the largest market share of 63.18% in 2022 and is estimated to retain the leading position during the forecast period. Women aged below 50 years are of reproductive age, and women’s health issues associated with this age group are more likely related to fertility, such as hormonal infertility, endometriosis, and polycystic ovary syndrome. According to the World Bank, in 2020, globally, around 64.8% of females were aged between 15 to 49 years, which is about 1.9 billion women out of 3.8 billion total female population. All these aforementioned factors boost the growth of the market. 

Regional Insights

North America dominated the overall market in 2022 and accounted for the maximum share of 41.16% of the global revenue. The region will expand further at a steady growth rate, maintaining its market position over the forecast period. This growth was attributed to the early approval & commercialization of products, favorable reimbursement policies, supportive government regulations, and high awareness about the importance of maintaining good health. For instance, in the financial year 2020-2021, the Government of Canada provided USD 50.47 million for family planning due to which 2.5 million women and couples received contraceptive supplies and services. 

Such initiatives and awareness campaigns will contribute to the market growth over the forecast period. Asia Pacific is expected to witness the fastest CAGR from 2023 to 2030 due to factors such as increasing awareness about women’s health and wellbeing, rising geriatric population, and various government initiatives for increasing health awareness. For instance, in July 2017, the Government of India increased its investment in family planning from US$ 2 billion to US$ 3 billion by 2020. In addition, as per the 2021-22 budget, the Australian government will invest USD 353.9 million over the next four years to support women’s health. 

Key Companies & Market Share Insights

Key market players are adopting strategies that allow them to use resources to develop new products. For instance, in September 2020, Bayer acquired KaNDy Therapeutics Ltd. This acquisition was expected to expand Bayer’s women’s health drug development pipeline. New players, such as TherapeuticsMD, Inc. & Mithra Pharmaceuticals SA, are entering the market with innovative products, and major players are collaborating with small companies for new product development. For instance, Pfizer, Inc. collaborated with Myovant Sciences for the commercialization and development of Relugolix. Additionally, Perrigo had applied for an Rx to OTC switch for its once daily Opill. The U.S. FDA has scheduled joint meetings with the Obstetrics, Reproductive, and Urologic Drugs Advisory Committee, the Nonprescription Drugs Advisory Committee on May 9 & 10, 2023 to discuss this application. Some of the key players in the women’s health market include:

• AbbVie, Inc.

• Bayer AG

• Merck & Co., Inc.

• Pfizer, Inc.

• Teva Pharmaceutical Industries Ltd.

• Agile Therapeutics

• Amgen, Inc.

• Apothecus Pharmaceutical Corp.

• Blairex Laboratories, Inc.

• Ferring B.V. 

Recent Developments

• In July 2023, Bayer announced a strategic partnership with Peking University to foster the transition of evolving pharmaceutical research to drug discovery & innovation, thereby boosting scientific research on groundbreaking technologies throughout the pharma value chain in China. This initiative is likely to open new growth avenues for the women’s health industry as well.

• In June 2023, Agile Therapeutics, Inc. announced its agreement with vitaCare Prescription Services for the expansion of access to patients access and streamlining fulfillment of Twirla transdermal system. Twirla is an advanced combined hormonal contraceptive patch that is used by women of reproductive potential.

• In April 2023, Ferring Pharmaceuticals entered into a collaboration with BioInnovation in order to boost advancements in the women’s health arena. The alliance includes supporting BioInnovation to source, fund, and incubate early-phase start-ups and projects within the reproductive medicine field.

• In January 2022, Agile Therapeutics, Inc. announced that it has entered into a strategic partnership with Afaxys Pharma, LLC for promoting Twirla transdermal system. This alliance was aimed at expanding the access of Twirla in the family planning community in the United States.

• In February 2021, Ferring entered into a collaboration with MyBiotics and Rebiotix for the development of microbiome-based live therapeutics in maternal health and reproductive medicine. This strategic initiative was purposed to create stabilized and standardized microbiota-based live formulations for addressing bacterial vaginosis.

Women’s Health Market Report Scope

Global Women’s Health Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global women’s health market report on the basis of age, application, and region:

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Postmenopausal Osteoporosis

  • Hormonal Infertility

  • Endometriosis & Uterine Fibroids

  • Contraceptives

  • Menopause

  • Polycystic Ovary Syndrome (PCOS)

• Age Outlook (Revenue, USD Million, 2018 - 2030)

  • 50 years and above

    • Postmenopausal Osteoporosis

    • Endometriosis & Uterine Fibroids

    • Menopause

    • Others

  • Others

• Regional Outlook (Revenue, USD Million; 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • U.K.

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • India

    • Japan

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait